Purpose of Review <p>In this review study, we address updated issues on the epidemiological situation of <i>C. auris</i> in South America as well as the development and application of select new therapeutic options against this pathogen, whether in vitro, in vivo studies and the approval stage.</p> Recent Findings <p>Cases of <i>C. auris</i> in South America have increased significantly in the last five years, especially due to the occurrence of the pandemic caused by the severe acute respiratory syndrome virus. New clades are being evaluated and the number of partically and pan-resistant strains has increased. In response, new alternative methods are being investigated or authorised for use against infection caused by <i>C. auris</i>.</p> Summary <p><i>Candidozyma auris (formally Candida auris)</i> is a globally emerging species of great clinical concern due to its multidrug-resistant capacity. <i>C. auris</i> is an opportunistic microorganism increasingly responsible for focal and systemic infections, particularly in immunocompromised and hospitalized patients. In South America, the first cases of <i>C. auris</i> emerged between 2012 and 2013 in Venezuela, and cases have since continued to increase, worrying the health sectors in the region. In South America, the incidence of candidemia varies from 0.74 to 6 per 1000 hospital admissions. Although <i>C. auris</i> is currently responsible for a small fraction of these, its incidence is predicted to continue to rise.</p> Graphical Abstract <p></p>